We report the synthesis of novel 1-(2′-deoxy-4′thio-β-D-erythro-pentofuranosyl)-(6-azapyrimidine) nucleosides and the subsequent preparation of a series of N 3 -substituted analogues. All the novel compounds were evaluated against a range of viruses, however they lacked any measurable activity. The lack of anti-herpetic activity may be a result of the parent nucleoside having poor affinity for herpes simplex virus type 1 thymidine kinase. Conformational analysis of the parent nucleoside showed a twist ( 3 T 2 ) sugar conformation commonly displayed by 2′-deoxy-4′-thionucleosides and the anti-human immunodeficiency virus type 1 agents zidovudine and 3′fluoro-ddT.
4′-Thionucleosides have become of increasing interest owing to their demonstrated resistance towards phosphorolytic cleavage and their broad range of biological activity (Walker, 1997) . 2′-deoxy-4′-thionucleosides, such as 4′-S-BVDU [IC 50 against herpes simplex virus type 1 (HSV-1), 0.6 µM; IC 50 HSV-2,~10 µM] (Dyson et al., 1991a) , have shown promise as anti-herpetic agents, but to date only one 4′-thio-6-aza-pyrimidine nucleoside has been prepared, a 2′-deoxyuridine nucleoside, 5-(2-thienyl)-6-aza-4′-thio-2′-deoxyuridine, which was shown to be an effective antiherpesvirus agent (IC 50 against HSV-1, 0.4 µM) (Basnak et al., 1998) . The stability shown by 6-aza-2′-deoxyuridines towards phosphorolysis makes them ideal candidates for targeting herpesviruses, and it was therefore decided to prepare the parent 6-azapyrimidine nucleoside 1 and the C-4 modified compounds 2 and 3 ( Figure 1 ).
The synthesis of N 3 -substituted azapyrimidine nucleosides (4-8, Figure 1 ) was of interest because N-alkylation of nucleosides has been shown to result in inhibition of DNA polymerase (for instance Escherichia coli DNA polymerase I) and avian myeloblastosis virus reverse transcriptase (Huff & Topal, 1987) . In some cases it also leads to reduced toxicity and longer plasma half-life (Adams et al., 1997) . Molecular modelling studies involving fitting thymidine-5′-triphosphate into the human immunodeficiency virus type 1 (HIV-1) reverse tran-scriptase active site (Adams et al., 1997) , indicated that the N 3 -position points directly into the enzyme cleft and theoretically should not experience difficulty accommodating functionality at this position.
Materials and Methods: Chemistry
1 H and 13 C NMR spectra were recorded with a Bruker Avance DPX300 spectrometer operating at 300 and 75 MHz, with Me 4 Si as the internal standard. FAB mass spectra were determined by the EPSRC mass spectrometry centre (Swansea, UK). Microanalyses were determined at the Department of Chemistry, Cardiff University. Flash column chromatography was performed with silica gel 60 (230-400 mesh; Merck) and TLC was carried out on precoated silica plates (kieselgel 60 F 254 , BDH). Melting points were determined on an electrothermal instrument and are uncorrected.
1-(3′,5′-di-O-benzyl-2′-deoxy-4′-thio-α/β-D-erythropentofuranosyl)-(6-azauracil) 11
To a suspension of 6-azauracil (3 g, 26.3 mmol) in dry acetonitrile (75 ml), N, O-bis(trimethylsilyl) acetamide (13 ml, 52.5 mmol) was added dropwise. The reaction was stirred under nitrogen at room temperature for 1 h, during which time a clear solution was formed. A solution of 2 (11.15 g, 30 mmol) in dry acetonitrile (75 ml) was then added and the Antiviral Chemistry & Chemotherapy 10:241-249 Novel 6-azapyrimidine-2′-deoxy-4′-thionucleosides: synthesis, biological evaluation and conformational analysis Introduction reaction mixture cooled to 0°C and trimethylsilyltrifluoromethane sulphonate (TMSOTf; 9.1 ml, 49.4 mmol) was added slowly. The reaction was then stirred at room temperature under nitrogen for 24 h. The reaction was diluted with dichloromethane (600 ml), washed with saturated aqueous sodium hydrogen carbonate (2×500 ml), dried (MgSO 4 ) and concentrated in vacuo to give a brown syrup that was purified by flash column chromatography (petroleum ether:ethyl acetate, 3:1 v/v) to give the product as a light yellow syrup. Yield: 10.11 g (90%, α:β 1:1), TLC system: petroleum ether:ethyl acetate 3:1 v/v, R F : 0.16. 1 H NMR (CDCl 3 ) mixture of anomers: δ 9.86 (s, 1 NH), 7.37 (s, 1H-5), 7.30 (m, 10, Ar), 6.40 (t, J=6.6 Hz, 1, H-1′), 4.57 (d, J=4.83 Hz, 2, CH 2 Ph), 4.52 (d, J=4.41 Hz, 2, CH 2 Ph), 4.44 (m, 1, H-3′), 3.67 (m, 2, H-4′ and H-5′), 3.53 (m, 1, H-5′), 2.48 (m, 2, H-2′). 13 C NMR (CDCl 3 ): δ 156. 29, 156.25 (2×CO, 148.23, 148 16 (2×CO, 138.56, 138.49, 138.46, 138.33 (4×, Ar), 136.49, 136.35 (2×C, 129.29, 129.15, 129.12, 129.07, 128.62, 128.54, 128.49, 128.42, 128.35, 127.67 (10×H, Ar), 83.17, 82.53 (CH, 73.89, 73.74, 73.22, 73.10 H, 5.44%, N, 9.87%; Found: C, 62.26%, H, 5.57%, N, 9.81%. 1-(2′-deoxy-4′-thio-α/β-D-erythro-pentofuranosyl)-(6-azauracil) 1α and 1β
To a cooled (-78°C) 1 M solution of boron trichloride in dichloromethane (36.2 ml, 36.2 mmol), a solution of 11 (3.8 g, 9 mmol) in dry dichloromethane (60 ml) was added dropwise. The reaction was stirred at -78°C for 3 h. A solution of methanol:dichloromethane (1:1 v/v, 100 ml) was added to quench the reaction, which was then allowed to reach room temperature. The solvent was removed in vacuo and the resulting residue co-evaporated with methanol (2×30 ml). The crude product was purified by flash column chromatography (chloroform:methanol, 85:15 v/v) 1′-(2′-deoxy-3′,5′-di-O-benzyl-4′-thio-αβ-D-erythropentofuranosyl)-(4-thio-6-azauracil) 12
To a stirred suspension of 1 (2 g, 4.7 mmol) in dry toluene (25 ml), p-methoxyphenylthionophosphine sulphide dimer (Lawesson's Reagent) (2.10 g, 5.2 mmol) was added. The reaction mixture was then heated under reflux overnight. The reaction was cooled to room temperature and the solvent was concentrated in vacuo, followed by co-evaporation with methanol to leave a thick orange oil, which was purified by flash column chromatography (petroleum ether:ethyl acetate, 1:1 v/v) to give the product 12 as an orange syrup. Yield: 1.47 g (72%), TLC system: petroleum ether:ethyl acetate, 1:1 v/v, R F : 0.80. 1 H NMR (CD 3 OD): δ 10.41 (s, 1, 7.33 (m, 11, 6.37 (t, J=6.8 Hz, 6.20 (dd, J 7.3, 7.5, 4.58 (m, 4, 2×H 2 Ph), 4.47 (m, 1, H-3′), 3.73 (m, 2, H-5′), 3.55 (m, 1, H-4′), 2.55 (m, 2, H-2′). 13 C NMR (CD 3 OD): δ 181. 71, 181.67 (C, C=S), 144.93, 144.82 (C, C=O), 141.68, 141.49 (CH, 138.17, 138.07, 137.94 (C, Ar), 128.80, 128.75, 128.71, 128.27, 128.15, 128.09, 128.06, 127.99, 127. 1′-(2′-deoxy-4′-thio-α/β-D-erythro-pentofuranosyl)-(4-thio-6-azauracil) 2α and 2β
To a cooled (-78°C) 1 M solution of boron trichloride in dichloromethane (10.75 ml, 10.7 mmol), a solution of compound 12 (1.9 g, 4.3 mmol) in dry dichloromethane (10 ml) was added dropwise. The solution was stirred for 3 h at -78°C and then quenched with a solution of methanol:dichloromethane (1:1 v/v, 10 ml). The reaction mixture was allowed to reach room temperature and the solvent was concentrated in vacuo, the resulting residue was co-evaporated with methanol (2×30 ml). Purification by flash column chromatography (petroleum ether:ethyl acetate, 3:1 then chloroform:methanol, 85:15 v/v) gave the products 2α and 2β as orange solids mixture of anomers α:β 1:1. 
6-azauracil) 13
To a stirred suspension of 1,2,4-triazole (2.7 g, 40 mmol) in dry acetonitrile (20 ml), phosphorus oxychloride (0.8 ml, 8.7 mmol) was added, then the reaction was cooled to 0°C and triethylamine (6 ml, 42.3 mmol) added. After stirring for 15 min, a solution of 1 (1 g, 2.3 mmol) in dry acetonitrile (10 ml) was added and the reaction was stirred overnight at room temperature. The reaction was quenched by the addition of 10% aqueous sodium hydrogen carbonate (100 ml) and the crude product extracted into dichloromethane (3×100 ml). The combined organic extracts were concentrated in vacuo to yield a light yellow syrup that was used without purification in the next step. TLC system: dichloromethane:methanol, 90:10 v/v. R F : 0.65.
Ammonia was bubbled into a solution of 13 (1.1 g, 2.3 mmol) in dichloromethane (40 ml) until saturation was achieved, then the reaction was left stirring at room temperature for 24 h. The reaction mixture was cooled to -80°C and ammonia gas bubbled into the reaction flask again, resulting in the addition of liquid ammonia (approximately 20 ml). After a further 5 h the reaction mixture was allowed to warm to room temperature and the solvent was concentrated in vacuo, to give a thick orange oil. Purification by flash column chromatography (dichloromethane:methanol 9:1, v/v) gave 14 as an orange solid. Yield: 600 mg (60.3%). TLC system: dichloromethane:methanol 9:1 v/v, R F : 0.42, m.p.: 56-57°C. 1 H NMR (CD 3 OD): δ 7.28 (m, 10, Ar), 6.33 (t, J=6.8 Hz, H-1′α), 6.24 (q, J=7.3 Hz, H-1′β), 4.45 (m, 4, CH 2 Ph), 3.99 154.41, 154.36 (C, CO), 137.74, 137.73, 137.69, 137.59 (C, Ar), 128.45, 127.60, 127.25, 127.14, 127.05, 126.99, 126.92, 126.27 
To a cooled (-78°C) 1 M solution of boron trichloride in dichloromethane (3.5 ml, 3.5 mmol) a solution of 14 (600 mg, 1.4 mmol) in dry dichloromethane (10 ml) was added dropwise. The solution was stirred for 3 h at -78°C and then quenched with a solution of methanol:dichloromethane (1:1 v/v, 10 ml). The reaction mixture was allowed to reach room temperature and the solvent concentrated in vacuo. The resulting residue was co-evaporated with methanol (2×30 ml). Purification by flash column chromatography (chloroform:methanol, 9:1 v/v) gave the product 3 as a light yellow syrup, as an inseparable mixture of anomers.
Yield: 98 mg (32%). General procedure for the synthesis of 1-(2′deoxy-4′-thio-β-D-erythro-pentofuranosyl)-(3-Nalkyl-6-azauracil) nucleosides 4-8
To a solution of 1β (50 mg, 0.2 mmol) in dry acetone (2 ml) and N,N-dimethylformamide (0.2 ml), potassium carbonate (47 mg, 0.34 mmol) was added and then the appropriate alkyl iodide (methyl, ethyl, butyl, hexyl 1-(2′-deoxy-4′-thio-β-D-erythro-pentofuranosyl)-(3-N-butyl-6-azauracil) 6
Yield: 38 mg (62%). R F : 0.38. 1 H NMR (CD 3 OD): δ 7.52 (s, 1, H-5), 6.32 (dd, J 1,2′endo =4.9 Hz, J 1′,2′exo =7.2 Hz, 1, H-1′), 4.61 (dd, J=5.1, 11.2 Hz, 1, H-3′), 3.85 (m, 3, H-5′a and CH 2 -butyl), 3.60 (dd, J=6.1, 11.2 Hz, 1, H-5′b), 3.37 (dd, J=6.6, 11.7 Hz, 1, H-4′), 2.67 (dt, J 2′endo,1′ =4.9, 9.8 Hz, 1, H-2′endo), 2.35 (dt, J 2′exo,1′ =7.1, 13.7 Hz, 1, H-2′exo), 1.60 (dt, J=7.0, 14.9 Hz, 2, CH 2 , butyl), 1.36 (dt, J=7.4, 15.0 Hz, 2, CH 2 , butyl), 0.99 (t, J=7.3, 14.6 Hz, 3, CH 3 butyl). 13 1-(2′-deoxy-4′-thio-β-D-erythro-pentofuranosyl)-(3-N-hexyl-6-azauracil) 7
Yield: 38 mg (57%). R F : 0.51. 1 H NMR (CD 3 OD): δ 7.48 (s, 1, H-5), 6.28 (dd, J 1′,2′endo =4.9 Hz, J 1′,2′exo =7.2 Hz, 1, H-1′), 4.57 (dd, J=5.1, 11.2 Hz, 1, H-3′), 3.80 (m, 3, H-5′a and CH 2 -hex), 3.56 (dd, J=6.8, 11.3 Hz, 1, H-5′b), 3.33 (dd, J=6.7, 11.7 Hz, 1, H-4′), 2.63 (dt, J 2′endo,1′ =4.9, 9.8 Hz, 1, H-2′endo), 2.30 (dt, J 2′exo,1′ =7.1, 13.7 Hz, 1, H-2′exo), 1.58 (t, J=6.2 Hz, 2, CH 2 , hex), 1.30 (s, 6, CH 2 , hex), 0.88 (t, J=6.5, 13.3 Hz, 3, CH 3 , hex). 13 C NMR (CD 3 OD); δ 156.20 (C, CO, C-4), 148.91 (C, CO, C-2), 134.92 (CH, C-5), 75.09 (CH, C-3′), 64.66 (CH 2 , C-5′), 63.29 (CH, C-1′), 57.94 (CH, C-4′), 40.75 (CH 2 , hex), 40.10 (CH 2 , C-2′), 31.49 (CH 2 , hex), 27.02 (CH 2 , hex), 26.53 (CH 2 , hex), 22.52 (CH 2 , hex), 13.29 (CH 3 , hex). MS (ES+) m/z: 329.9 (M+H) + .
1-(2′-Deoxy-4′-thio-β-D-erythro-pentofuranosyl)-(3-N-octyl-6-azauracil) 8
Yield: 45 mg (63%). R F : 0.48. 1 H NMR (CD 3 OD): δ 7.52 (s, 1, H-5), 6.32 (dd, J 1′,2′endo =4.9 Hz, J 1′,2′exo =7.1 Hz, 1, H-1′), 4.62 (dd, J=5.8, 11.2 Hz, 1, H-3′), 3.84 (m, 3, H-5′a and CH 2 -oct), 3.60 (dd, J=6.9, 12.2 Hz, 1, H-5′b), 3.35 (bm, 1, H-4′), 2.67 (dt, J 2′endo,1′ =4.9, 9.8 Hz, 1, H-2′endo), 2.35 (dt, J 2′exo,1′ =7.3, 13.8 Hz, 1, H-2′exo), 1.62 (t, J 6.4, 2, CH 2 -oct), 1.32 (d, J=7.7 Hz, 10, CH 2 -oct), 0.91 (t, J=5.3 Hz, 3, CH 3 -oct). 13 C NMR (CD 3 OD): δ 156.21 (C, CO, C-4), 148.91 (C, CO, C-2), 134.93 (CH, C-5), 75.09 (CH, C-3′), 64.66 (CH 2 , C-5′), 63.30 (CH, C-1′), 57.94 (CH, C-4′), 40.75 (CH 2 , oct), 40.10 (CH 2 , C-2′), 31. 90, 29.22, 27.05, 26.84, 22 .66 (CH 2 , oct), 13.38 (CH 3 , oct). MS (ES+) m/z: 358.0 (M+H) + .
X-ray structure determination and conformational analysis
The X-ray measurements were made on a crystal of approximate dimensions 0.25×0.11×0.11 mm. Unit cell and intensity data were obtained at 150 K using a Delft Instruments FAST TV area detector diffractometer and graphite mono-chromated Mo-κ α radiation (λ=0.71069 Å) (Lehmann et al. 1993) . Compound 1β, FW=246.27, crystallizes in the monoclinic space group I2/m, with a=16.461 (4), b=6.776 (1), c=18.822 (3) Å, B=102.77 (3) deg., V=2047.5 (7) A 3 , z=8, D calc =1.598 g cm -3 and µ (Mo-κ α )=0.321 mm -1 .
The total data recorded within θ range of 1.86 to 24.94°w as 2551, which merged to give 2375 unique data (R merge =0.049) of which 1636 were considered observed (F o >2σ(F)). The data were corrected for Lorentz and polarization effects.
The structure was solved using direct methods (Sheldrick, 1990) and refined by full matrix least squares (Sheldrick, 1997) to give a final R value of 0.0414 for 293 parameters. The absolute structure of the crystal was -0.20 (14) established by the method described by Flack (1983) . The non-hydrogen atoms were refined anisotropically and the hydrogen values included in idealized positions.
Atomic co-ordinates, displacement factor coefficients, full list of bond lengths and angles, and F o /F c values have been deposited with the Editor-in-Chief, from whom copies are available on request.
Phase angle and degree of amplitude (P and υ m ) were determined using the equations (a) and (b) respectively as described by Altona & Sundaralingam (1972) : Equation (a) tanP = (υ 4 +υ 1 ) -(υ 3 +υ 0 )/2υ 2 (sin 36+sin 72).
Materials and Methods: Virology

Enzyme assay
The radiolabelled substrate [methyl-3 H]dThd (70 Ci/mmol) was obtained from Amersham Pharmacia Biotech. The enzyme activity was assayed in a 50 µl reaction mixture containing 50 mM Tris-HCl pH 8.0, 2.5 mM MgCl 2 , 10 mM DTT, 0.5 mM CHAPS, 3 mg/ml BSA, 2.5 mM ATP, 1 µM [methyl-3 H]dThd, varying concentrations of inhibitor and recombinant enzyme. The samples were incubated at 37°C for 30 min. Aliquots of 45 µl of the reaction mixtures were spotted on Whatman DE-81 filter paper disks. The filters were washed three times for 5 min in 1 mM NH 4 OOCH 3 , once for 1 min in water and once for 5 min in ethanol. The radioactivity was determined by scintillation counting.
Experiments with virus-infected cell cultures
The antiviral assays, other than the anti-HIV-1 assays, were based on inhibition of virus-induced cytopathicity in either E 6 SM, HeLa, Vero, or HEL cell cultures, following previously established procedures (De Clercq et al., 1980 Schols et al., 1990) . Briefly, confluent cell cultures in microtitre trays were inoculated with 100 CCID 50 of virus, 1 CCID 50 being the virus dose required to infect 50% of the cell cultures. After a 1 h virus adsorption period, residual virus was removed and the cell cultures were incubated in the presence of varying concentrations (400, 200, 100 µg/ml, and so on) of the test compounds. Viral cytopathicity was recorded as soon as it reached completion in the control virus-infected cell cultures.
Inhibition of HIV-induced giant cell formation
CEM cell cultures were suspended at 250000-300000 cells/ml of culture medium and infected with HIV-1 (III B ) or HIV-2 (ROD) at 100 CCID 50 /ml. Then, 100 µl of the infected cell suspension was transferred to 200 µl microtitre plate wells containing 100 µl of serial dilutions of the test compound solutions. After 4 days of incubation at 37°C, cell cultures were examined for syncytium formation as previously described (Balzarini et al., 1991) .
Chemistry
The 4′-thionucleoside 1 was prepared by the reaction of the thiosugar 9 (Dyson et al., 1991b) with the bis-silylated azauracil base 10 in the presence of the Lewis acid TMSOTf. This Vorbrüggen methodology (Vorbrüggen et al., 1981) resulted in the best yields and anomeric ratio (90%, α:β 1:1). Deprotection of 1 with boron trichloride allowed the separation of the anomers (Figure 2) . Confirmation of anomeric configuration was obtained by 1 H NMR (Table 1 ) and X-ray crystallography (Figure 3) . Modification of the base moiety involved conversion of 1 into the C-4 thiocarbonyl 12 by reaction with Lawesson's reagent (Cava & Levinson, 1985) . Separation of the anomers was achieved after deprotection to give 2α and 2β. Conversion of 1 into the corresponding 6-aza-cytidine derivative 3 via the triazole intermediate 13 proceeded well, however at no stage was it possible to separate the individual anomers ( Figure 4) .
The synthesis of 2′-deoxy-4′-thiocytidine has been reported by Secrist et al. (1991) . In this case the anomer-ic mixture of the cytidine derivatives could not be separated at either the protected or deprotected stage, necessitating the use of the pure β-uridine nucleoside as the precursor in order to obtain the required β-cytidine nucleoside.
It was possible to distinguish between the anomers of 1 and 2 from the chemical shift of H-1′ with H-1′β occurring further downfield than H-1′α. The H-2′ signal splitting patterns were very distinctive with a multiplet for H-2′α and two doublets of triplets for H-2′β separated by 0.2 p.p.m; this characteristic H-2′ splitting pattern was previously observed for the 2′-deoxy-4′-thio-imidazole nucleosides (Wang et al., 1999) .
Alkylation at N-3 of 1β was achieved in moderate yields Synthesis of novel 6-azapyrimidine-2′-deoxy-4′-thionucleosides 7 Antiviral Chemistry & Chemotherapy 10:5 *Koole et al., 1992 by reaction with a range of alkyl iodides in the presence of potassium carbonate (Yamamoto et al., 1987) to give a novel library of 1′-(3-N-alkyl-6-azauracil)-2′-deoxy-4′thio-β-D-pentofuranosides 4-8 (Table 2) .
Conformational analysis
The parent nucleoside, 1-(2′-deoxy-4′-thio-β-D-erythropentofuranosyl)-(6-azauracil) 1β, crystallizes with two independent molecules in the unit cell (molecules A and B) ( Figure 3 ). Selected geometrical parameters (Altona & Sundaralingam, 1972) for the parent nucleoside 1β are described in Table 3 and compared with 2′-deoxy-4′-thiothymidine (4′S-T) (Koole et al., 1992) , a known substrate for viral thymidine kinase (TK) that displays activity against HSV (Walker, 1997) . Molecules A and B of compound 1β are essentially isomorphous with a C2′-endo/3′-exo twist ( 3 T 2 ) sugar conformation commonly displayed by 2′-deoxy-4′-thionucleosides (Koole et al., 1992) and the anti-HIV agents zidovudine and 3′-fluoro-ddT (Van Roey et al., 1990) . The X-ray crystallographic data indicates an anti conformation [torsional angle χ=-110.9°and -120.47°, molecules (a) and (b) respectively]. The major difference between 1β, 4′S-T and the antiviral 2′,3′-dideoxynucleosides (ddNs) is the conformation about the C4′-C5′ bond, with a gauche-trans (g-or -sc) orientation for 1β compared with trans (or ap-) orientation for 4′S-T and the ddNs.
Antiviral activity
The antiviral activity of compounds 1β-8 were evaluated against HSV-1 (strain KOS) and HSV-2 (strain G), human cytomegalovirus (HCMV), varicella-zoster virus (VZV), HIV-1 and HIV-2, reovirus 1, Coxsackie virus B4, Sindbis virus, parainfluenzavirus 3 and Punta Toro virus. All of the compounds were inactive at subtoxic concentrations, 20 µM for 6 and 8, and 100 µM for the other compounds. Compound 1β was not inhibitory to HSV-1 TK at 100 µM.
Discussion
There is a general structural similarity of 1β with 4′S-T and the other known 4′-thio-6-aza-nucleoside, 5-(2thienyl)-6-aza-4′-thio-2′-deoxyuridine, making it not unreasonable to expect 1β to be a potential substrate for HSV-1 TK. In addition, it is known that 2′-deoxyuridine is a substrate for cellular TK-1 and herpetic HSV-1 and HSV-2 TK ( Johansson et al., 1999) . The test compounds, including 1β, were not inhibitory to [methyl-3 H]dThd phosphorylation by purified HSV-1 TK at 100 µM, that is at a drug concentration that was 100-fold higher than the dThd concentration used in the assay. Therefore, it is assumed that the compounds have a very poor affinity, or may even completely lack any affinity, for the enzyme to be recognized as a substrate. Therefore, the potential lack of substrate activity for HSV-1 TK may explain why 1β and its N 3 -substituted derivatives lacked any measurable antiviral activity.
The lack of any significant activity displayed by 1β (and therefore 2-8) may also result from an unfavourable conformation. Conformational analysis of reverse transcriptase inhibitors has shown that the 3′-exo (and to a lesser extent 2′-endo) character of the sugar moiety with a trans (ap) C4′-C5′ conformation is the most favourable conformation with regards to biological activity. Therefore, the transgauche (g-) orientation about the C4′-C5′ bond of 1β may well explain the difference in activity between 1β and 4′S-T and the ddNs. However, this does not explain the difference in activity between 1β and 5-(2-thienyl)-6-aza-4′-thio-2′-deoxyuridine, because both share the same C4-C5′ geometry. It should be mentioned that thymidine analogues always have a much better affinity for nucleoside kinases than 2′-deoxyuridine analogues lacking the 5-methyl substituent. Therefore, 5-substituted pyrimidine nucleosides often display potent anti-herpesvirus activity (Lin et al., 1995; De Clercq & Walker, 1986) , and particularly the additional 2-thienyl substituent at C-5 of 5-(2-thienyl)-6-aza-4′-thio-2′-deoxyuridine results in marked activity against HSV. It would therefore be of interest to prepare 5-substituted 2′-deoxy-4′-thio-6-azapyrimidine nucleosides for further biological evaluation against herpesviruses.
